icell gene therapeutics LLC

2 white pine lane
e. setauket, new york 11733

NYS Entity Status
ACTIVE

NYS Filing Date
SEPTEMBER 05, 2014

NYS DOS ID#
4632201

County
SUFFOLK

Jurisdiction
NEW YORK

Registered Agent
YUPO MA
2 WHITE PINE LANE
E.SETAUKET, NEW YORK, 11733

NYS Entity Type
DOMESTIC LIMITED LIABILITY COMPANY

Name History
2014 - ICELL GENE THERAPEUTICS LLC
2014 - I CELL GENE THERAPEUTICS LLC









Buffer

submit to reddit

Telephone
n/a

Fax
n/a

Website
n/a

Email address
n/a

LinkedIn
n/a

Facebook
n/a

Google+
n/a

Twitter
n/a

Pinterest
n/a

Instagram
n/a



  • Around the Web

  • For Parkinson’s, Two New Drugs Coming As Prevail Gets Started in NY
    By Ben Fidler - Wednesday Aug 9, 2017

    A drug that actually slows or reverses the brain damage inflicted by Parkinson’s disease, rather than just alleviates its often debilitating symptoms, remains elusive. But Prevail Therapeutics, a startup just launched in New York, has become the latest to try. This morning, the Silverstein Foundation, a nonprofit organization formed by OrbiMed partner Jonathan Silverstein, announced […]

    Source: Xconomy New York
  • Gene Editing Is Here, and Desperate Patients Want It
    Thursday Oct 12, 2017

    Two-thirds of Americans support therapeutic use, but regulators are still stuck in the 1970s.

    Source: The Wall Street Journal: Opinion
  • Dragonfly, eGenesis, Spero & More: Xconomy’s Startup Award Finalists
    By Corie Lok - Monday Aug 14, 2017

    Startups play a critical role in the innovation economy that we chronicle at Xconomy—transforming new ideas that begin in a lab into the products and companies of tomorrow. No surprise, then, that the startup category in our first-ever Awards program was a particularly competitive one, loaded with private companies (no more than 5 years old) […]

    Source: Xconomy New York
  • Bio Roundup: PDUFA Progress, BCRA Redux, CAR-T Thumbs Up, & More
    By Frank Vinluan - Friday Jul 14, 2017

    Government and industry are rife with awkward acronyms. Take PDUFA, for example. First passed in 1992, the Prescription Drug User Fee Act allows the FDA to collect fees from biopharmaceutical companies when they apply for drug approval; those funds are designated for the regulator’s drug evaluation work. Congress must reauthorize the law every five years […]

    Source: Xconomy New York
  • FDA advisers endorse gene therapy to treat form of blindness
    By MATTHEW PERRONE, AP Health Writer - Thursday Oct 12, 2017

    SILVER SPRING, Md. (AP) — A potentially groundbreaking treatment for a rare form of blindness moved one step closer to U.S. approval Thursday, as federal health advisers endorsed the experimental gene therapy for patients with an inherited condition that gradually destroys eyesight.The panel experts to the Food and Drug Administration voted unanimously in favor of Spark Therapeutics' injectable therapy, which aims to improve vision by replacing a defective gene needed to process light.The vote amounts to a recommendation to approve the therapy. The FDA has until mid-January to make its decision and does not have to follow the panel's recommendation, though it often does.If approved, Luxturna would be the first gene therapy in the U.S.

    Source: SFGATE.com: Top News Stories